Education
About Us
Working with TipRanks
Follow Us
Grand Pharmaceutical Group Limited (HK:0512)
:0512
0512 Stock Chart & Stats
HK$7.80
-HK$0.03(-0.67%)
At close: 4:00 PM EST
HK$7.80
-HK$0.03(-0.67%)
Day’s Range― - ―
52-Week RangeHK$4.70 - HK$10.20
Previous CloseN/A
Volume1.96M
Average Volume (3M)9.26M
Market Cap
HK$26.80B
Enterprise ValueHK$30.47B
Total Cash (Recent Filing)HK$1.81B
Total Debt (Recent Filing)HK$4.61B
Price to Earnings (P/E)12.7
Beta0.73
Next Earnings
Mar 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.13%
Share Statistics
EPS (TTM)0.33
Shares Outstanding3,549,571,000
10 Day Avg. Volume7,622,050
30 Day Avg. Volume9,255,379
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)1.02
Price to Sales (P/S)1.44
P/FCF Ratio13.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$11.88Price Target Upside52.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthGrand Pharm shows multi-year top-line expansion (CAGR ~12%, recent revenue growth ~10.6%). Durable revenue growth supports scaling hospital access, funds R&D and registrations, and reduces reliance on single products—underpinning sustainable competitive positioning over the next 2–6 months.
High Gross MarginsA sustained gross margin above 50% indicates favorable product mix and pricing power in hospital and clinical channels. This margin buffer supports investment in commercialization and R&D, helps absorb SG&A or tender pricing pressure, and underpins long-term margin resilience.
Positive Operating Cash FlowConsistent positive operating cash flow demonstrates cash-generative core operations, enabling reinvestment, debt servicing and working capital without relying on external financing. Strong cash conversion supports strategic capex, product approvals and near-term commercial scale-up.
Bears Say
Collapsed EBIT MarginAn EBIT margin falling to ~0% signals material operating-profit pressure. That erosion reduces internal funding for R&D and commercialization, narrows flexibility on tender pricing, and increases dependence on scale or cost cuts to restore sustainable operating profitability over several quarters.
Material Free Cash Flow DeclineA one-third drop in free cash flow from higher capex tightens the cash cushion for dividends, M&A or deleveraging. If elevated capex persists it can strain liquidity and force trade-offs between growth investments and short-term financial flexibility across the coming 2–6 months.
Earnings And ROE PressureNegative EPS growth (~-13.6%) alongside a slightly declining ROE indicates weakening profitability and returns on capital. Persisting earnings pressure can limit internal funding, reduce investor confidence, and hinder the company's ability to sustain growth investments or improve margins in the near term.
Grand Pharmaceutical Group Limited News
0512 FAQ
What was Grand Pharmaceutical Group Limited’s price range in the past 12 months?
Grand Pharmaceutical Group Limited lowest stock price was HK$4.70 and its highest was HK$10.20 in the past 12 months.
What is Grand Pharmaceutical Group Limited’s market cap?
Grand Pharmaceutical Group Limited’s market cap is HK$26.80B.
When is Grand Pharmaceutical Group Limited’s upcoming earnings report date?
Grand Pharmaceutical Group Limited’s upcoming earnings report date is Mar 18, 2026 which is in 24 days.
How were Grand Pharmaceutical Group Limited’s earnings last quarter?
Grand Pharmaceutical Group Limited released its earnings results on Aug 19, 2025. The company reported HK$0.334 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.334.
Is Grand Pharmaceutical Group Limited overvalued?
According to Wall Street analysts Grand Pharmaceutical Group Limited’s price is currently Undervalued.
Does Grand Pharmaceutical Group Limited pay dividends?
Grand Pharmaceutical Group Limited pays a Annually dividend of HK$0.26 which represents an annual dividend yield of 3.13%. See more information on Grand Pharmaceutical Group Limited dividends here
What is Grand Pharmaceutical Group Limited’s EPS estimate?
Grand Pharmaceutical Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Grand Pharmaceutical Group Limited have?
Grand Pharmaceutical Group Limited has 3,549,571,000 shares outstanding.
What happened to Grand Pharmaceutical Group Limited’s price movement after its last earnings report?
Grand Pharmaceutical Group Limited reported an EPS of HK$0.334 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.444%.
Which hedge fund is a major shareholder of Grand Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:0512
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grand Pharmaceutical Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.42%
12-Months-Change
Fundamentals
Return on Equity
12.65%
Trailing 12-Months
Asset Growth
6.29%
Trailing 12-Months
Company Description
Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers pharmaceutical preparations, including cerebro-cardiovascular emergency medicines; respiratory, ophthalmic, anti-infection, and ENT medicines; oncology medicines; and rare disease medicines. It also provides medical devices, such as vascular interventional medical devices comprising paclitaxel releasing coronary balloon dilatation catheters and paclitaxel releasing hemodialysis shunt balloon dilatation catheters; and ophthalmology related devices. In addition, the company offers biotechnology and health products, such as Taurine, amino acid products, steroid products, and bio-pesticides and agricultural antibiotics; and specialized pharmaceutical raw materials and other products, including metronidazole, chloramphenicol, epinephrine, dimethyl sulfate, nitromethane, etc. Further, the company offers agrochemicals, fine chemicals, and chemical medicines; ophthalmic gel and eye drops; steroid hormones active pharmaceutical ingredients and related intermediates; bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. Grand Pharmaceutical Group Limited has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited and changed its name to Grand Pharmaceutical Group Limited in November 2021. Grand Pharmaceutical Group Limited was incorporated in 1995 and is based in Central, Hong Kong.
0512 Stock 12 Month Forecast
Average Price Target
HK$11.88
▲(52.31% Upside)
Technical Analysis
HUTCHMED (China)
―
The United Laboratories International Holdings
―
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Options Prices
Currently, No data available
---